Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
1. JNJ's stock hit a Golden Cross, signaling potential long-term growth. 2. Short-term averages indicate mixed signals, suggesting selling pressure. 3. Breakthrough in lung cancer treatment could drive long-term revenue. 4. Major milestone achieved with improved survival rates in Phase 3 study. 5. Technical indicators are bullish, but short-term resistance may pose challenges.